The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sparebanken Ost
LSE:0G45
|
NO |
|
K
|
Komipharm International Co Ltd
KOSDAQ:041960
|
KR |
|
C
|
Celon Pharma SA
WSE:CLN
|
PL |
|
Y
|
Youngchang Chemical Co Ltd
KOSDAQ:112290
|
KR |
|
B
|
Barloworld Ltd
JSE:BAW
|
ZA |
|
V
|
Velocity Minerals Ltd
F:VMSP
|
CA |
|
F
|
Fintech SA
WSE:FTH
|
PL |
|
Hedef Holding AS
IST:HEDEF.E
|
TR |
|
G
|
Gentili Mosconi SpA
MIL:GM
|
IT |
|
S
|
S 11 Group PCL
SET:S11
|
TH |
|
F
|
Fittech Co Ltd
TWSE:6706
|
TW |
|
S
|
SemiLEDs Corp
SWB:6LD1
|
TW |
|
A
|
Anima Holding SpA
F:124
|
IT |
|
TZ Ltd
ASX:TZL
|
AU |
|
ProQR Therapeutics NV
F:0PQ
|
NL |
|
H
|
Hubei Huaqiang High-Tech Co Ltd
SSE:688151
|
CN |
|
Centurion Acquisition Corp
NASDAQ:ALF
|
US |
|
M
|
Mainland Headwear Holdings Ltd
HKEX:1100
|
HK |
|
Arcosa Inc
NYSE:ACA
|
US |
|
CapitaLand Ascott Trust
OTC:ATTRF
|
SG |
|
F
|
Fractyl Health Inc
NASDAQ:GUTS
|
US |
Sparebanken Ost (0G45)’s 12-month stock price forecast through April 2027 has a consensus target of kr78.42, implying 2% downside. The forecast is based on price targets from 4 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
0G45 is 78.42 NOK with a low forecast of 76.62 NOK and a high forecast of 81.81 NOK.
Over the last 13 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 3 years is -3%.
Over the last 13 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 3 years is 46%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more